Soligenix Inc
SNGX3.110USD
+0.370+13.50%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
9.90MValor de mercado
PerdaP/L TTM
Mais detalhes de Soligenix Inc Empresa
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Informações da empresa
Código da empresaSNGX
Nome da EmpresaSoligenix Inc
Data de listagemApr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 04
Endereço29 Emmons Drive
CidadePRINCETON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08540
Telefone16095388200
Sitehttps://www.soligenix.com/
Código da empresaSNGX
Data de listagemApr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
Investidores
Investidores
Proporção
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
Tipos de investidores
Investidores
Proporção
Hedge Fund
3.11%
Investment Advisor/Hedge Fund
0.90%
Investment Advisor
0.54%
Individual Investor
0.02%
Other
95.43%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
50
149.55K
4.58%
-122.83K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
2023Q2
61
91.32K
18.32%
+80.79K
2023Q1
62
7.29K
3.99%
-8.64K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Connective Capital Management, LLC
101.63K
3.11%
+101.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
29.37K
0.9%
+3.27K
+12.55%
Mar 31, 2025
UBS Financial Services, Inc.
10.47K
0.32%
+10.16K
+3244.73%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
3.59K
0.11%
-1.00
-0.03%
Mar 31, 2025
The Vanguard Group, Inc.
3.18K
0.1%
--
--
May 31, 2025
Schaber (Christopher J)
379.00
0.01%
--
--
Apr 21, 2025
Plante Moran Financial Advisors, LLC
300.00
0.01%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
223.00
0.01%
--
--
Mar 31, 2025
Zeldis (Jerome B)
96.00
0%
--
--
Apr 21, 2025
Northern Trust Investments, Inc.
72.00
0%
+72.00
--
Dec 31, 2023
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Data
Tipo
Proporção
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
